Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 661

1.

Characterization of compound 584, an Abl kinase inhibitor with lasting effects.

Puttini M, Redaelli S, Moretti L, Brussolo S, Gunby RH, Mologni L, Marchesi E, Cleris L, Donella-Deana A, Drueckes P, Sala E, Lucchini V, Kubbutat M, Formelli F, Zambon A, Scapozza L, Gambacorti-Passerini C.

Haematologica. 2008 May;93(5):653-61. doi: 10.3324/haematol.12212. Epub 2008 Mar 26.

2.

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.

Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M.

ChemMedChem. 2009 Jan;4(1):118-26. doi: 10.1002/cmdc.200800320.

PMID:
19039816
3.

Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.

Liu H, Li H, Feng Z, Tai J, Meng Y, Wang H, Xin H, Zhang S, Zuo M, Zhang Y, Chen X.

Leuk Lymphoma. 2009 Mar;50(3):437-46. doi: 10.1080/10428190802709438.

PMID:
19347730
4.

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T.

Blood. 2007 Jan 1;109(1):306-14. Epub 2006 Sep 5.

5.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
6.

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47.

7.

Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.

Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, Miura O.

Oncogene. 2007 May 10;26(21):2975-87. Epub 2006 Nov 27.

PMID:
17130834
8.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
9.

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.

O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93.

10.

Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.

Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J.

Cancer Res. 2006 May 15;66(10):5387-93.

11.
12.
13.

[An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes].

Von Bubnoff N, Peschel C, Duyster J.

Dtsch Med Wochenschr. 2004 Oct 1;129(40):2100-3. German.

PMID:
15455301
14.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD.

Cancer Cell. 2005 Feb;7(2):129-41. Erratum in: Cancer Cell. 2005 Apr;7(4):399. Mohammed, Azam [corrected to Azam, Mohammad].

15.

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB.

J Pharmacol Exp Ther. 2000 Oct;295(1):139-45.

16.

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.

Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T.

Blood. 2005 Dec 1;106(12):3948-54. Epub 2005 Aug 16.

17.

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes T.

Blood. 2005 Oct 1;106(7):2520-6. Epub 2005 Jun 14.

18.

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C.

J Natl Cancer Inst. 1999 Jan 20;91(2):163-8.

PMID:
9923858
19.

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.

Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27.

PMID:
19039322
20.

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.

Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyons JF, Thompson NT, Ashihara E, Ottmann OG, Maekawa T.

Blood. 2010 Sep 23;116(12):2089-95. doi: 10.1182/blood-2009-03-211466. Epub 2010 Jun 14.

Supplemental Content

Support Center